Search

Introduction. The cases of reactivation of chronic HBV hepatitis were described in rheumatology and then in hematology. Usually, HBV relapses are described after the third cure of biological therapy in both rheumatologic and hematologic pathology. Purpose. The assessment and monitoring of developments in the treatment of a woman with chronic HBV reactivated after biologic therapy with Rituximab for a small B-cell non-Hodgkin's lymphoma who developed also chronic kidney disease. Results. We present the case of a 36 years old woman with reactivation of chronic HBV hepatitis after biological therapy with Rituximab (cure 9) for non Hodgkin's lymphoma with small B-cell. We initiate lamivudine therapy for one month; thereafter we continue with entecavir (dose adjusted to the glomerular filtration rate), together with Rituximab, with favorable outcome both in hematological pathology, as well as in chronic HBV hepatitis, respectively in the biochemical and virology response. Conclusions. In our case, the patient followed the trend of most cases described in the literature, with return to normal ALT values and viral negativity, but without HBs seroconversion. [ABSTRACT FROM AUTHOR]